Oxytocin Phase 2 Trial for Binge-Eating Disorder Recruiting

A clinical trial studying oxytocin in adults with binge-eating disorder was listed as recruiting on August 14, 2026. The study, registered as NCT05664516 on ClinicalTrials.gov, is titled "A Study of the Effects of Oxytocin in Adults With Binge-eating Disorder." It is designated as a Phase 2 trial. According to the registry, the current status of the trial is recruiting, meaning it is actively enrolling participants. Oxytocin is an approved compound, and this trial represents an ongoing investigation into its effects in this specific patient population. No results or outcome data have been posted for this trial at this stage. The trial record does not specify further details beyond its phase, status, and title as of the listed date. Readers interested in tracking this study's progress can refer to the official ClinicalTrials.gov listing for updates on enrollment, timeline, and eventual outcomes. For more background on oxytocin as a compound, including its approved uses and general profile, see the linked compound overview.